Try our beta test site
104 studies found for:    Open Studies | HIV or AIDS | NIAID
Show Display Options
Rank Status Study
1 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
2 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
3 Recruiting Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Condition: HIV Infections
Interventions: Drug: Maraviroc;   Drug: Placebo
4 Recruiting Evaluating the Safety and Pharmacokinetics of VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1-Exposed Infants
Condition: HIV Infections
Intervention: Biological: VRC01
5 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
6 Recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
7 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
8 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01
9 Recruiting Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 28 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
Condition: HIV Infections
Interventions: Drug: Lamivudine/zidovudine;   Drug: Efavirenz;   Drug: Raltegravir
10 Recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
11 Recruiting Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Condition: HIV Infections
Interventions: Drug: Dolutegravir (DTG) film-coated tablets;   Drug: DTG granules for suspension;   Drug: DTG dispersible tablets
12 Recruiting Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
13 Recruiting Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
Condition: HIV Infections
Interventions: Drug: Romidepsin;   Drug: Placebo for RMD: 0.9% sodium chloride for injection
14 Recruiting Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
15 Not yet recruiting Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
Condition: HIV Infections
Interventions: Drug: Dolutegravir;   Drug: Emtricitabine/tenofovir alafenamide;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
16 Recruiting Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA
17 Recruiting Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND)
Condition: HIV Infections
Interventions: Drug: Placebo for maraviroc (MVC);   Drug: Placebo for dolutegravir (DTG);   Drug: Dolutegravir (DTG);   Drug: Maraviroc (MVC)
18 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01;   Drug: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
19 Not yet recruiting Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Maraviroc
20 Recruiting Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Raltegravir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.